New Telcagepant Trial To Start This Year
Drug company Merck is planning to start a new trial for the drug Telcagepant this year, a spokeswoman for the company says.
We last talked about this up-and-coming migraine drug back in October (see New Migraine Drug Telcagepant – Not Dead Yet. It shows promise, but Merck stopped trials of Telcagepant as a preventative when some patients showed elevated levels of liver enzymes (read more here).
Merck took some time to discuss options with FDA (USA) officials. After some months, they have decided to go ahead with another safety trial in 2010, though they’re still working to design the study.
Telcagepant is one of a group of drugs called CGRP receptor antagonists. Many patients who haven’t benefited from triptan type drugs are looking forward to trying Telcagepant. However, researchers are also interested to see how Telcagepant and other CGRP receptor antagonists will work along with triptans.
Stay tuned to find out more about this upcoming study, and the results. Also, we hope to see other drugs in this class researched for migraine.